DaVita Inc. (NYSE:DVA) China affiliate agreed to invest CNY 147 million ($22.87 million) in Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998)'s unit for 31.7% stake. says it plans to buy pharma firm for up to CNY 185.8 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.84 CNY | +0.17% | -0.84% | +8.03% |
Apr. 19 | Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 10 | Fangsheng Pharma's Factories Pass GMP Inspection | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.03% | 719M | |
+15.37% | 41.97B | |
+22.56% | 22.34B | |
+15.23% | 15.25B | |
+16.53% | 14B | |
+49.78% | 12.06B | |
-10.77% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- 603998 Stock
- News Hunan Fangsheng Pharmaceutical Co., Ltd.
- Davita's China Affiliate to Invest in Hunan Fangsheng Pharma's Unit for 31.7% Stake